Overview

This trial is active, not recruiting.

Condition ovarian cancer, peritoneal neoplasms
Sponsor Hoffmann-La Roche
Start date October 2012
End date June 2017
Trial size 63 participants
Trial identifier NCT01788995, ML28355

Summary

This non-interventional study will evaluate the routine use and the safety and efficacy of Avastin (bevacizumab) as first-line treatment in patients with advanced ovarian cancer (epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma). Newly diagnosed patients who are initiated on carboplatin/paclitaxel chemotherapy in combination with Avastin will be followed for up to 15 months of treatment and 12 months of follow-up.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm

Primary Outcomes

Measure
Clinical/demographic patient characteristics at initiation of treatment
time frame: approximately 4 years
Duration of treatment
time frame: approximately 4 years
Treatment discontinuations/modifications
time frame: approximately 4 years

Secondary Outcomes

Measure
Safety: Incidence of adverse events
time frame: approximately 4 years
Progression-free survival
time frame: approximately 4 years

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Adult patients, >/= 18 years of age - Patients with newly diagnosed advanced epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC) with indication for first-line carboplatin/paclitaxel chemotherapy in combination with Avastin Exclusion Criteria: - Contraindications for Avastin according to the Summary of Product Characteristics

Additional Information

Official title A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Hoffmann-La Roche.